 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Improved Treatment of AL Amyloidosis
20 January 2004 | Volume 140 Issue 2 | Page I-27
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study." It is in the 20 January 2004 issue of Annals of Internal Medicine (volume 140, pages 85-93). The authors are M. Skinner, V. Sanchorawala, D.C. Seldin, L.M. Dember, R.H. Falk, J.L. Berk, J.J. Anderson, C. O'Hara, K.T. Finn, C.A. Libbey, J. Wiesman, K. Quillen, N. Swan, and D.G. Wright.
What is the problem and what is known about it so far?
Bone marrow consists of several kinds of cells. These cells manufacture many chemicals known as proteins. One kind of bone marrow cell (plasma cell) makes a protein called amyloid that is produced in different forms. One form is lighter in weight than others. Abnormal plasma cells may produce too much light amyloid, which results in a disease called AL amyloidosis. This protein is then deposited in different organs, causing progressive disability and death. Without treatment, patients usually die within about a year. If amyloid deposits affect the heart, death occurs more rapidly (in about 5 months). Treatment with a drug called melphalan destroys abnormal plasma cells and, when given by mouth, can lengthen survival. A promising new approach to treatment involves giving high-dose melphalan intravenously. However, this approach also kills normal bone marrow cells, which must then be replaced. This is done by collecting a special type of cell (known as stem cells) from the patient's bone marrow or blood before melphalan is administered and then giving them back to the patient (a process known as autologous stem-cell transplantation) after melphalan administration. Stem cells can regenerate normal bone marrow cells that have been lost during melphalan treatment.
Why did the researchers do this particular study?
To determine whether high-dose melphalan treatment and autologous stem-cell transplantation could improve survival in AL amyloidosis.
Who was studied?
701 consecutive patients with AL amyloidosis who took part in 6 different studies over 8 years.
How was the study done?
The researchers reviewed the results of 312 patients with AL amyloidosis who were treated with high-dose melphalan and stem-cell transplantation and compared them with results from other patients who were not eligible for this treatment. They looked for evidence of persistent AL amyloidosis after treatment and at how long each patient survived. They also determined how well different organs were working.
What did the researchers find?
Half of all patients who received treatment survived for more than 4.5 years. Of 137 patients with heart involvement, half were alive after 1.5 years. Of those without heart involvement, half were alive after 6.5 years. Forty percent of treated patients had no evidence of AL amyloidosis after treatment (complete remission). Of those who remained in complete remission 1 year after treatment, 8% had relapses within 2 years but none had relapses after 2 years. Half of the patients who were not eligible for the treatment died within 4 months.
What were the limitations of the study?
Patients were collected from 6 different studies conducted over 6 years. Each study had somewhat different methods and chose different types of patients. Patients who were excluded from treatment (the comparison group) were older and sicker than those in the treatment group.
What are the implications of the study?
Treatment with high-dose melphalan and stem-cell transplantation can improve survival, even in patients with heart involvement.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mignot, F. Bridoux, A. Thierry, S. Varnous, M. Pujo, A. Delcourt, J. M. Gombert, J.-M. Goujon, F. Favreau, G. Touchard, et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis Haematologica, March 1, 2008; 93(3): e32 - e35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bollee, B. Guery, D. Joly, R. Snanoudj, B. Terrier, M. Allouache, L. Mercadal, M.-N. Peraldi, B. Viron, C. Fumeron, et al. Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bochtler, U. Hegenbart, C. Heiss, A. Benner, F. Cremer, M. Volkmann, J. Ludwig, J. B. Perz, A. D. Ho, H. Goldschmidt, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis Haematologica, March 1, 2008; 93(3): 459 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-U. Sack, A. Kristen, H. Goldschmidt, P. A. Schnabel, T. Dengler, A. Koch, and M. Karck Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhou, J. Teruya-Feldstein, P. Lu, M. Fleisher, A. Olshen, and R. L Comenzo Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan Blood, January 15, 2008; 111(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kumar, A. Dispenzieri, M. A. Gertz, J. Mehta, H. J. Lachmann, A. D. Wechalekar, J. D. Gillmore, H. M. Lokhorst, B. P.C. Hazenberg, A. Croockewit, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N. Engl. J. Med., January 3, 2008; 358(1): 91 - 92. [Full Text] [PDF]
|
|
|
|
|
|
J. Mehta Amyloidosis: graviores morbos, asperis remedii Blood, November 15, 2007; 110(10): 3490 - 3491. [Full Text] [PDF]
|
|
|
|
|
|
V. Sanchorawala, M. Skinner, K. Quillen, K. T. Finn, G. Doros, and D. C. Seldin Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Blood, November 15, 2007; 110(10): 3561 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF]
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, S. K. Kumar, N. Leung, and D. A. Gastineau Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response Haematologica, October 1, 2007; 92(10): 1415 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, B. Asli, B. Lioure, B. Royer, et al. High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis N. Engl. J. Med., September 13, 2007; 357(11): 1083 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Palladini, P. Russo, M. Nuvolone, F. Lavatelli, V. Perfetti, L. Obici, and G. Merlini Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis Blood, July 15, 2007; 110(2): 787 - 788. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Salant, V. Sanchorawala, and V. D. D'Agati A Case of Atypical Light Chain Deposition Disease--Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 858 - 867. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Dember, P. N. Hawkins, B. P.C. Hazenberg, P. D. Gorevic, G. Merlini, I. Butrimiene, A. Livneh, O. Lesnyak, X. Puechal, H. J. Lachmann, et al. Eprodisate for the Treatment of Renal Disease in AA Amyloidosis N. Engl. J. Med., June 7, 2007; 356(23): 2349 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Leung, A. Dispenzieri, M. Q. Lacy, S. K. Kumar, S. R. Hayman, F. C. Fervenza, S. S. Cha, and M. A. Gertz Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Schechter A triple on AL amyloidosis, waiting for a home run Blood, January 15, 2007; 109(2): 391 - 392. [Full Text] [PDF]
|
|
|
|
|
|
V. Sanchorawala, D. G. Wright, M. Rosenzweig, K. T. Finn, S. Fennessey, J. B. Zeldis, M. Skinner, and D. C. Seldin Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial Blood, January 15, 2007; 109(2): 492 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Wechalekar, H. J. B. Goodman, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis Blood, January 15, 2007; 109(2): 457 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Dember Amyloidosis-Associated Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini Refining therapy for AL amyloidosis Blood, December 1, 2006; 108(12): 3632 - 3633. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, M. Skinner, K. Malek, D. G. Wright, K. Quillen, K. Finn, B. Oran, and V. Sanchorawala Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65 Blood, December 1, 2006; 108(12): 3945 - 3947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini and M. J. Stone Dangerous small B-cell clones Blood, October 15, 2006; 108(8): 2520 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol, October 1, 2006; 142(10): 1298 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Palladini, F. Lavatelli, P. Russo, S. Perlini, V. Perfetti, T. Bosoni, L. Obici, A. R. Bradwell, G. M. D'Eril, R. Fogari, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL Blood, May 15, 2006; 107(10): 3854 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Rihova, M. Merta, I. Spicka, J. Zabka, R. Rysava, M. Chochola, E. Meisnerova, I. Vitkova, C. Povysil, J. Reiterova, et al. Unusual manifestation of AL amyloidosis--stenosis of inferior vena cava Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1430 - 1433. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Comenzo, P. Zhou, M. Fleisher, B. Clark, and J. Teruya-Feldstein Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins Blood, May 1, 2006; 107(9): 3489 - 3491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dispenzieri, M. Q. Lacy, J. A. Katzmann, S. V. Rajkumar, R. S. Abraham, S. R. Hayman, S. K. Kumar, R. Clark, R. A. Kyle, M. R. Litzow, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood, April 15, 2006; 107(8): 3378 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Blood, March 15, 2006; 107(6): 2578 - 2584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Buxbaum Treatment and prevention of the amyloidoses: Can the lessons learned be applied to sporadic inclusion-body myositis? Neurology, January 24, 2006; 66(1_suppl_1): S110 - S113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Donato, A. M. Feasel, D. M. Weber, V. G. Prieto, S. A. Giralt, R. E. Champlin, and M. Duvic Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation Blood, January 15, 2006; 107(2): 463 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Leung, T. R. Leung, S. S. Cha, A. Dispenzieri, M. Q. Lacy, and M. A. Gertz Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients Blood, November 15, 2005; 106(10): 3353 - 3357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Falk Diagnosis and Management of the Cardiac Amyloidoses Circulation, September 27, 2005; 112(13): 2047 - 2060. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ng, L. H. Connors, R. Davidoff, M. Skinner, and R. H. Falk Senile Systemic Amyloidosis Presenting With Heart Failure: A Comparison With Light Chain-Associated Amyloidosis Arch Intern Med, June 27, 2005; 165(12): 1425 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Dember, J.-A. O. Shepard, F. Nesta, and J. R. Stone Case 15-2005 - An 80-Year-Old Man with Shortness of Breath, Edema, and Proteinuria N. Engl. J. Med., May 19, 2005; 352(20): 2111 - 2119. [Full Text] [PDF]
|
|
|
|
|
|
G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Blood, April 1, 2005; 105(7): 2949 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Komatsuda, N. Maki, H. Wakui, H. Ohtani, T. Hatakeyama, T. Yasuda, Y. Nakamoto, H. Imai, and K.-i. Sawada Development of systemic {lambda}-light chain amyloidosis in a patient with {gamma}-heavy chain deposition disease during long-term follow-up Nephrol. Dial. Transplant., February 1, 2005; 20(2): 434 - 437. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Seldin Interfering with amyloidosis Blood, December 1, 2004; 104(12): 3419 - 3420. [Full Text] [PDF]
|
|
|
|
|
|
M. V. Dhodapkar, M. A. Hussein, E. Rasmussen, A. Solomon, R. A. Larson, J. J. Crowley, and B. Barlogie Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628 Blood, December 1, 2004; 104(12): 3520 - 3526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, and J.-P. Fermand Best therapy for primary amyloidosis, a not-yet-solved question Blood, November 1, 2004; 104(9): 2990 - 2991. [Full Text] [PDF]
|
|
|
|
|
|
H. J. B. Goodman, P. N. Hawkins, A. Dispenzieri, M. A. Gertz, R. A. Kyle, and J. Mehta The role of PBSCT in treatment of AL amyloidosis is far from settled Blood, November 1, 2004; 104(9): 2991 - 2994. [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini Sharpening therapeutic strategy in AL amyloidosis Blood, September 15, 2004; 104(6): 1593 - 1594. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, V. Sanchorawala, K. Malek, D. G. Wright, K. Quillen, K. T. Finn, J. L. Berk, L. M. Dember, R. H. Falk, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation Blood, September 15, 2004; 104(6): 1888 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mehta High-dose therapy for amyloidosis: the end of the beginning? Blood, May 15, 2004; 103(10): 3612 - 3613. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Gertz, G. Merlini, and S. P. Treon Amyloidosis and Waldenstrom's Macroglobulinemia Hematology, January 1, 2004; 2004(1): 257 - 282. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
